19
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      De-isolation of COVID-19-positive hemodialysis patients in the outpatient setting: a single-center experience.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the editor: The advice for patients presenting with COVID-19 symptoms is to self-isolate for 7 days after the onset of symptoms for the individual case, and 14 days for the household 1 . Dialysis patients can be considered as immuno-compromised and display a decreased ability to develop seroconversion to infectious diseases 2 . Therefore, 7-14 days may not be an appropriate threshold in a dialysis population. In our centre, we provide dialysis in 2 hospital-based and 6 satellite units, for a total of 664 patients. We cohorted our COVID-19 positive dialysis outpatients in a dedicated unit and followed a pathway for de-escalation of stable patients using serial COVID-19 swabs, starting 7 days after confirmed diagnosis (Figure 1 ). (Supplementary Table S1). 34 COVID-19 positive patients who had at least 3 swabs were included: 20 patients were de-isolated in less than 14 days (59%) with 9% on day 9. By day 12, 35% of patients could be dialysed in their base unit (which is crucial for capacity). However, by day 15, 14 patients (41%) had not cleared the virus and could not be repatriated: 5 patients cleared the virus later (median of 18 days (range 16-21)) and 9 patients were still positive or had only one negative swab at the end of follow-up. It is unclear if detection of viral RNA represents the ability to transmit the virus 3 , 4 , but until more evidence is available, it would be prudent to isolate patients as discussed to prevent cross-contamination in this high-risk population. Figure 1 De-escalation plan for COVID-19 positive dialysis patients, HD; Haemodialysis Disclosures Dr. Simon Goldenberg reports personal fees from Astellas, personal fees from Enterobiotix, personal fees from Menarini, personal fees from MSD, personal fees from Pfizer, personal fees from Shionogi, outside the submitted work.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: not found

          Temporal dynamics in viral shedding and transmissibility of COVID-19

          We report temporal patterns of viral shedding in 94 patients with laboratory-confirmed COVID-19 and modeled COVID-19 infectiousness profiles from a separate sample of 77 infector-infectee transmission pairs. We observed the highest viral load in throat swabs at the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset. We estimated that 44% (95% confidence interval, 25-69%) of secondary cases were infected during the index cases' presymptomatic stage, in settings with substantial household clustering, active case finding and quarantine outside the home. Disease control measures should be adjusted to account for probable substantial presymptomatic transmission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Targeting Immunity in End-Stage Renal Disease

            Background: Despite the stable incidence of end-stage renal disease (ESRD), it continues to be associated with an unacceptably high cardiovascular risk. Summary: ESRD is characterized by enhanced oxidative stress and severe inflammation, which boost cardiovascular risk, thus increasing cardiovascular-associated mortality rate. While substantial effort has been made in the technological innovation of dialytic techniques, few significant advances have been made to reduce inflammation in patients with ESRD. Indeed, this contrasts with the extensive scientific breakthroughs made in the basic field of science in targeting inflammation. There is thus a pressing need for clinical trials to test the effect of reducing inflammation in patients with ESRD. Here, we will revisit the negative effect of ESRD on inflammation and explore the impact of enhanced inflammation on cardiovascular outcomes and survival in patients with ESRD. Finally, we will discuss the need for clinical trials that target inflammation in ESRD, as well as weigh potential disadvantages and offer novel innovative approaches. Key Message: We will try to understand why the issue of inflammation has not been successfully addressed thus far in patients with ESRD, while at the same time weighing the potential disadvantages and offering novel innovative approaches for targeting inflammation in patients with ESRD.
              Bookmark

              Author and article information

              Journal
              Kidney Int.
              Kidney international
              Elsevier BV
              1523-1755
              0085-2538
              July 2020
              : 98
              : 1
              Affiliations
              [1 ] Renal Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
              [2 ] Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
              [3 ] Renal Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: dimitrios.moutzouris@gstt.nhs.uk.
              Article
              S0085-2538(20)30437-3
              10.1016/j.kint.2020.04.021
              7206422
              32471644
              45557a0d-601c-4974-a030-08df456da968
              History

              Comments

              Comment on this article